Steep Hill Inc (TSE:STPH)
:STPH
Want to see TSE:STPH full AI Analyst Report?
Top Page
Steep Hill Inc
(STPH)
Select Model
Select Model
Rating:49Neutral
Price Target:
C$0.06
▼(-8.33% Downside)
Action:Reiterated
Date:12/30/25
The score is held back primarily by weak and unstable operating results and recent cash burn despite a low-debt balance sheet. Technical signals are neutral-to-soft, while valuation looks optically cheap on P/E but is discounted by earnings quality concerns. The reverse takeover and related restructuring/financing are meaningful potential catalysts but introduce significant execution and transition risk.
Positive Factors
Strategic Acquisition
The acquisition of Lir Life Sciences positions Steep Hill in the biopharmaceutical sector, potentially expanding its market reach and product offerings, which could enhance long-term growth prospects.
Negative Factors
Lack of Revenue
The absence of revenue poses a significant risk to Steep Hill's long-term sustainability, as it limits the company's ability to fund operations and growth initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic Acquisition
The acquisition of Lir Life Sciences positions Steep Hill in the biopharmaceutical sector, potentially expanding its market reach and product offerings, which could enhance long-term growth prospects.
Read all positive factors
Steep Hill Inc (STPH) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$1.75M
Dividend YieldN/A
Average Volume (3M)12.40K
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue GrowthN/A
EPS Growth-176.78%
CountryCA
Employees6
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.14
Shares Outstanding2,914,864
10 Day Avg. Volume9,973
30 Day Avg. Volume12,401
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.12
Price to Sales (P/S)0.00
P/FCF Ratio-0.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Steep Hill Inc Business Overview & Revenue Model
Company Description
Steep Hill Inc., a cannabis science and technology company, provides laboratory testing, quality assurance, and data analytics services in Canada and the United States. It offers analytical testing services, such as cannabinoids, terpenes, pestici...
How the Company Makes Money
Steep Hill Inc generates revenue primarily through its laboratory testing services. Key revenue streams include fees charged for cannabis potency testing, which measures the levels of THC and CBD present in products, and safety screening for conta...
Steep Hill Inc Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
68
Positive
Cash Flow
31
Negative
| Breakdown | TTM | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 1.18M | 938.57K | 0.00 |
| Gross Profit | -3.84K | -15.37K | -16.64K | 1.18M | 938.57K | -118.78K |
| EBITDA | -197.36K | -188.23K | -444.66K | -3.73M | -3.97M | -1.95M |
| Net Income | 384.74K | 337.71K | 793.30K | -7.12M | -4.53M | -2.08M |
Balance Sheet | ||||||
| Total Assets | 2.08M | 2.28M | 2.76M | 3.02M | 7.43M | 1.70M |
| Cash, Cash Equivalents and Short-Term Investments | 2.03M | 2.21M | 2.61M | 1.91M | 2.58M | 438.63K |
| Total Debt | 0.00 | 0.00 | 18.55K | 79.97K | 718.20K | 442.48K |
| Total Liabilities | 162.30K | 258.56K | 1.11M | 2.17M | 1.73M | 551.85K |
| Stockholders Equity | 1.91M | 2.02M | 1.65M | 842.34K | 5.77M | 1.20M |
Cash Flow | ||||||
| Free Cash Flow | -206.75K | -381.46K | 742.34K | -1.82M | -1.57M | -1.56M |
| Operating Cash Flow | -206.75K | -381.46K | 742.34K | -1.82M | -1.57M | -1.25M |
| Investing Cash Flow | 150.00K | 0.00 | -2.00M | 1.48M | -336.96K | -280.03K |
| Financing Cash Flow | -3.46K | -19.06K | -53.22K | -253.84K | 4.04M | 402.02K |
Steep Hill Inc Technical Analysis
Positive
0.06
Price Trends
0.06
Negative
0.06
Positive
0.06
Positive
Market Momentum
>-0.01
Negative
49.24
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:STPH, the sentiment is Positive. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and above the 200-day MA of 0.06, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.24 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:STPH.
Steep Hill Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | C$33.99M | -8.58 | -19.10% | ― | 0.66% | -14.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$22.49M | 2.74 | -71.80% | ― | -7.53% | 41.77% | |
50 Neutral | C$66.92M | -10.33 | -19.76% | ― | -100.00% | 87.93% | |
49 Neutral | C$1.75M | -2.15 | -13.46% | ― | ― | -176.78% | |
41 Neutral | C$51.16M | -10.76 | ― | ― | -62.34% | 9.80% |
* Healthcare Sector Average
TSE:STPH
Steep Hill Inc
0.60
0.24
67.13%
TSE:ATLE
Willow Biosciences Inc
0.19
>-0.01
-4.52%
TSE:QNTM
Quantum Biopharma
10.96
-6.14
-35.91%
TSE:LABS
MediPharm Labs
0.08
<0.01
14.29%
TSE:BNXT
BioNxt Solutions
0.42
-0.12
-22.22%
TSE:INNO
InnoCan Pharma
5.00
-5.40
-51.92%
Steep Hill Inc Corporate Events
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesM&A TransactionsPrivate Placements and FinancingStock Split
Steep Hill Advances Reverse Takeover and Rebrand with Good Purpose Investments
Positive
Dec 20, 2025
Steep Hill Inc. has amended and advanced its previously announced three‑cornered amalgamation with Good Purpose Investments Inc., under which Steep Hill will acquire all issued and outstanding Good Purpose securities in a reverse takeover th...
Business Operations and StrategyM&A Transactions
Steep Hill Inc. to Merge with Good Purpose Investments in Strategic Shift
Neutral
Nov 13, 2025
Steep Hill Inc. has announced an amalgamation agreement with Good Purpose Investments, marking a significant shift in its business operations. This transaction, which involves a reverse takeover, will result in Steep Hill changing its name to Good...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.